Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
To estimate the efficacy and safety of tislelizumab for stage IVA locally advanced
nasopharyngeal carcinoma combined with induction chemotherapy and concurrent
chemoradiotherapy, followed by maintenance therapy
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences